CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 3 Insider Initial Statement of Ownership
- PRE 14A Proxy Proxy Statement (Preliminary)
- 8-K Event Executive or director change
- 8-K Event Agreement ended
- 4 Grant or award EVP, Chief Scientific Officer acquired 37,966 shares (grant or award)
- 4 Open-market sale EVP, General Counsel sold 2,297 shares at $32.99 ($75,778)
- 4 Grant or award EVP, Chief Business Officer acquired 29,393 shares (grant or award)
- 4 Open-market sale EVP, Chief Technical Officer sold 605 shares at $32.99 ($19,959)
- 4 Grant or award President and CEO acquired 113,586 shares (grant or award)
- 4 Grant or award EVP, Chief Medical Officer acquired 38,701 shares (grant or award)
- 4 Grant or award EVP, Chief Financial Officer acquired 28,628 shares (grant or award)
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 8-K Event Material agreement
- S-8 Other Securities Offered to Employees in Benefit Plans
Page 9 of 37 · 725 filings